Real-time Estimate
Cboe BZX
09:41:25 2024-05-20 am EDT
|
5-day change
|
1st Jan Change
|
3.205
USD
|
-5.46%
|
|
-4.24%
|
-40.84%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
908.3
|
383.1
|
506.7
|
306.2
|
-
|
-
|
Enterprise Value (EV)
1 |
908.3
|
383.1
|
506.7
|
306.2
|
306.2
|
306.2
|
P/E ratio
|
-7.15
x
|
-3.83
x
|
-4.15
x
|
-1.84
x
|
-1.62
x
|
-1.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
94.6
x
|
27.7
x
|
14.7
x
|
26.1
x
|
24.4
x
|
4.08
x
|
EV / Revenue
|
94.6
x
|
27.7
x
|
14.7
x
|
26.1
x
|
24.4
x
|
4.08
x
|
EV / EBITDA
|
-13.8
x
|
-3.66
x
|
-4.5
x
|
-1.75
x
|
-1.5
x
|
-4.86
x
|
EV / FCF
|
-
|
-
|
-4.83
x
|
-2.02
x
|
-1.61
x
|
-1.47
x
|
FCF Yield
|
-
|
-
|
-20.7%
|
-49.6%
|
-62.2%
|
-67.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
60,192
|
61,002
|
88,431
|
90,318
|
-
|
-
|
Reference price
2 |
15.09
|
6.280
|
5.730
|
3.390
|
3.390
|
3.390
|
Announcement Date
|
3/21/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
9.598
|
13.85
|
34.48
|
11.74
|
12.57
|
74.97
|
EBITDA
1 |
-
|
-66
|
-104.8
|
-112.5
|
-174.6
|
-204.7
|
-63.01
|
EBIT
1 |
-
|
-66.98
|
-106.4
|
-116.1
|
-184
|
-237.4
|
-232.5
|
Operating Margin
|
-
|
-697.84%
|
-768.17%
|
-336.63%
|
-1,567.28%
|
-1,889.03%
|
-310.13%
|
Earnings before Tax (EBT)
1 |
-
|
-66.6
|
-99.35
|
-101.9
|
-170.8
|
-229.1
|
-229.4
|
Net income
1 |
-34.31
|
-66.92
|
-99.42
|
-102.1
|
-166.7
|
-217.6
|
-213.2
|
Net margin
|
-
|
-697.26%
|
-717.79%
|
-296.05%
|
-1,419.86%
|
-1,731.53%
|
-284.4%
|
EPS
2 |
-7.300
|
-2.110
|
-1.640
|
-1.380
|
-1.841
|
-2.087
|
-1.948
|
Free Cash Flow
1 |
-
|
-
|
-
|
-104.9
|
-151.9
|
-190.4
|
-207.7
|
FCF margin
|
-
|
-
|
-
|
-304.27%
|
-1,293.35%
|
-1,515.15%
|
-277.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/7/21
|
3/21/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2.559
|
2.664
|
4.192
|
3.303
|
3.692
|
3.502
|
3.755
|
23.66
|
3.558
|
2.429
|
3.038
|
2.95
|
3.364
|
4.25
|
4.75
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-36.7
|
-
|
-43.14
|
-44.97
|
-46.87
|
-
|
-
|
EBIT
1 |
-20.4
|
-20.85
|
-28.43
|
-26.54
|
-30.58
|
-31.12
|
-32.87
|
-14.63
|
-37.44
|
-46
|
-44.89
|
-46.76
|
-48.36
|
-53.7
|
-58.03
|
Operating Margin
|
-797.38%
|
-782.77%
|
-678.22%
|
-803.42%
|
-828.22%
|
-888.52%
|
-875.31%
|
-61.84%
|
-1,052.33%
|
-1,893.87%
|
-1,477.45%
|
-1,585.07%
|
-1,437.44%
|
-1,263.44%
|
-1,221.77%
|
Earnings before Tax (EBT)
1 |
-18.16
|
-19.09
|
-26.7
|
-26.65
|
-26.92
|
-28.04
|
-29.52
|
-10
|
-34.31
|
-41.23
|
-42.29
|
-44.34
|
-46.25
|
-51.37
|
-55.91
|
Net income
1 |
-18.48
|
-19.09
|
-26.7
|
-26.65
|
-26.99
|
-28.04
|
-29.52
|
-10
|
-34.5
|
-41.23
|
-40.91
|
-42.58
|
-44.19
|
-51.37
|
-55.91
|
Net margin
|
-722.12%
|
-716.52%
|
-636.86%
|
-806.75%
|
-731.01%
|
-800.8%
|
-786.13%
|
-42.27%
|
-969.79%
|
-1,697.57%
|
-1,346.33%
|
-1,443.46%
|
-1,313.51%
|
-1,208.6%
|
-1,176.98%
|
EPS
2 |
-0.3100
|
-0.3200
|
-0.4400
|
-0.4400
|
-0.4400
|
-0.4600
|
-0.4800
|
-0.1200
|
-0.3900
|
-0.4600
|
-0.4551
|
-0.4738
|
-0.4840
|
-0.5300
|
-0.5800
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/21/22
|
5/9/22
|
8/9/22
|
11/8/22
|
3/9/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/11/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-105
|
-152
|
-190
|
-208
|
ROE (net income / shareholders' equity)
|
-
|
-36.7%
|
-28.9%
|
-30.5%
|
-50.6%
|
-79.1%
|
-23.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-24.4%
|
-25.3%
|
-54.6%
|
-216%
|
-174%
|
Assets
1 |
-
|
-
|
408.1
|
403
|
305.4
|
100.6
|
122.5
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-1.030
|
-1.500
|
-1.260
|
-1.130
|
-2.150
|
-2.590
|
Capex
1 |
-
|
2.12
|
-
|
11.6
|
8.2
|
10.8
|
11.2
|
Capex / Sales
|
-
|
22.1%
|
-
|
33.68%
|
69.83%
|
85.63%
|
14.91%
|
Announcement Date
|
5/7/21
|
3/21/22
|
3/9/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
3.39
USD Average target price
19.75
USD Spread / Average Target +482.60% Consensus |
1st Jan change
|
Capi.
|
---|
| -40.84% | 306M | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|